Profile data is unavailable for this security.
About the company
NanoViricides, Inc. is a development stage company, which is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other advanced candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 is its nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2-R is its other drug candidate for COVID-19, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates, NV-CoV-2 and NV-CoV-2-R independently. It is also developing drugs against a number of viral diseases, including RSV, oral and genital Herpes, viral diseases of the eye, including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu and others.
- Revenue in USD (TTM)0.00
- Net income in USD-9.36m
- Incorporated2005
- Employees7.00
- LocationNanoViricides Inc1 Controls DriveSHELTON 06484United StatesUSA
- Phone+1 (203) 937-6137
- Fax+1 (203) 859-5095
- Websitehttp://www.nanoviricides.com/
